SELECTED PUBLICATIONS
Mohammad, H. P.; Smitheman, K. N.; Kamat, C. D.; Soong, D.; Federowicz, K. E.; Van Aller, G. S.; Schneck, J. L.; Carson, J. D.; Liu, Y.; Butticello, M.; Bonnette, W. G.; Gorman, S. A.; Degenhardt, Y.; Bai, Y.; McCabe, M. T.; Pappalardi, M. B.; Kasparec, J.; Tian, X.; McNulty, K. C.; Rouse, M.; McDevitt, P.; Ho, T.; Crouthamel, M.; Hart, T. K.; Concha, N. O.; McHugh, C. F.; Miller, W. H.; Dhanak, D.; Tummino, P. J. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell 2015, 28(1), 57-69.
Verma, S.; Tian, X.; LaFrance, L. V.; Duquenne, C.; Suarez, D. P.; Newlander, K. A.; Romeril, S. P.; Burgess, J.; Grant, S. W.; Brackley, J. A.; Scherzer, D. A.; Shu, A.; Graves, A. P.; Thompson, C. S.; Ott, H.; Van Aller, G. S.; Machutta, C.; Johnson, N. W.; Knight, S. D.; Kruger, R. G.; McCabe, M. T.; Dhanak, D.; Tummino, P.; Creasy, C. L.; Miller, W. H. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med. Chem. Lett. 2012, 3(12), 1091–1096.
Miles, T. J.; Axten, J. M.; Barfoot, C.; Brooks, G.; Brown, P.; Chen, D.; Dabbs, S.; Davies, D. T.; Downie, D. L.; Eyrisch, S.; Gallagher, T.; Giordano, I.; Gwynn, M. N.; Hennessy, A.; Hoover, J.; Huang, J.; Jones, G.; Markwell, R.; Miller, W. H.; Minthorn, E. A.; Rittenhouse, S.; Seefeld, M.; Pearson, N. Novel amino-piperidines as potent antibacterials targeting bacterial type II topoisomerases. Bioorg. Med. Chem. Lett. 2011, 21, 7489-7495.
Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; DeWolf, W. E., Jr.; Elkins, P. A.; Head, M. S.; Jakas, D. R.; Janson, C. A.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Payne, D. J.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Uzinskas, I. N.; Wallis, N. G.; Huffman, W. F. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem. 2003, 46, 1627-1635.
Miller, W. H.; Alberts, D. P.; Bhatnagar, P. K.; Bondinell, W. E.; Callahan, J. F.; Calvo, R. R.; Cousins, R. D.; Erhard, K. F.; Heerding, D. A.; Keenan, R. M.; Kwon, C.; Manley, P. J.; Newlander, K. A.; Ross, S. T.; Samanen, J. M.; Uzinskas, I. N.; Venslavsky, J. W.; Yuan, C. C. K.; Haltiwanger, R. C.; Gowen, M.; Hwang, S.-M.; James, I. E.; Lark, M. W.; Rieman, D. J.; Stroup, G. B.; Azzarano, L. M.; Salyers, K. L.; Smith, B. R.; Ward, K. W.; Johanson, K. O.; Huffman, W. F. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J. Med. Chem. 2000, 43, 22-26.
Selected US Patents
Ellis, J. L.; Evans, K. A.; Fox, R. M.; Miller, W. H.; Seefeld, M. A. Substituted bridged urea analogs as sirtuin modulators. US 10,072,011, issued September 11, 2018.
Johnson, N. W.; Kasparec, J.; Rouse, M. B.; Tian, X.; Miller, W. H.; Suarez, D. Cyclopropylamines as LSD1 inhibitors. US 9,346,840, issued 24 May 2016.
Brackley III, J.; Burgess, J. L.; Grant, S.; Johnson, N.; Knight, S. D.; LaFrance, L.; Miller, W. H.; Newlander, K.; Romeril, S.; Rouse, M. B.; Tian, X.; Verma, S. K. Indoles. US 8,975,291, issued 10 March 2015.
Duffy, K. J.; Miller, W. H.; Myers, A. K.; Shaw, A. N.; Zimmerman, M. N. N-substituted glycine derivatives: hydroxylase inhibitors. US 7,608,621, issued 27 October 2009, and RE 44,613 (reissue of US 7,608,621), issued 26 November 2013.
Miller, W. H.; Newlander, K. A.; Seefeld, M. A.; Uzinskas, I. N.; DeWolf, W. E., Jr.; Jakas, D. R. FabI inhibitors. US 8,173,646, issued 08 May 2012.
Miller, W. H.; Pendrak, I.; Seefeld, M. A. Antibacterial agents. US 7,691,850, issued 06 April 2010.
Callahan, J. F.; Cousins, R. D.; Keenan, R. M.; Kwon, C.; Miller, W. H.; Uzinskas, I. N. Vitronectin receptor antagonists. US 6,825,188, issued 30 November 2004.